A recent analysis from Cornell University highlights the risks associated with postponing the birth dose of the Hepatitis B vaccine in newborns. The study found that delaying vaccination leads to an increase in infections, poorer survival outcomes, and higher healthcare costs. Depending on how long the first dose is deferred and how well subsequent doses are completed, the estimated economic burden ranged from approximately $16 million to $370 million. These findings were published in JAMA Pediatrics.1
Chronic hepatitis B remains a major global health concern, as it can progress to cirrhosis, liver failure, and hepatocellular carcinoma. Infants are particularly vulnerable: nearly 90% of those infected at birth develop chronic infection, and about one-quarter may die prematurely from liver-related complications.2 Because of this high risk, preventing transmission at birth is considered a key component of hepatitis B control strategies.
In December 2025, the Advisory Committee on Immunization Practices revised its earlier recommendation by suggesting that infants born to mothers who test negative for hepatitis B surface antigen could delay the first vaccine dose. This marked a shift from the prior policy advocating universal vaccination within 24 hours of birth. To assess the impact of such changes, researchers developed probabilistic models incorporating vaccine efficacy, transmission dynamics, and disease progression.
The study compared multiple scenarios, including administration of the first vaccine dose at birth versus delays until 2 months, 7 months, 4 years, or even 12 years. These models also accounted for different maternal infection statuses and varying levels of adherence to the full vaccination schedule. Across all scenarios, delayed vaccination was associated with higher rates of chronic infection and long-term complications such as cirrhosis and liver cancer. The negative impact was even more pronounced when children did not complete the recommended three-dose series.1
Importantly, the authors noted that their estimates were conservative. The models did not account for increased exposure risk from infected household or community members, which could further elevate infection rates if vaccination coverage declines. The current low prevalence of hepatitis B in countries like the United States is largely attributed to successful universal immunization programs.2,3
Another concern raised is that postponing the initial vaccine dose may reduce overall vaccine completion rates. Evidence suggests that children who start vaccination later are less likely to complete the full series, potentially undermining long-term disease control efforts.3
Safety concerns were also reviewed. Extensive data spanning more than three decades indicate that hepatitis B vaccines are highly safe, with no consistent evidence linking them to serious adverse effects such as neurological disorders, seizures, or increased mortality. Moreover, long-term follow-up studies demonstrate sustained immunogenicity and protection, often lasting into adulthood.4
In summary, delaying the birth dose of hepatitis B vaccine may increase the risk of infection, worsen health outcomes, and raise healthcare costs. Current evidence strongly supports maintaining universal vaccination at birth as the most effective strategy to prevent hepatitis B transmission and its long-term complications.
References
1- Nelson N, et al. Economic evaluation of delaying the infant hepatitis B vaccination schedule. JAMA Pediatr. 2026;
2- World Health Organization. Hepatitis B fact sheet. Geneva: WHO; 2023.
3- Centers for Disease Control and Prevention. Hepatitis B vaccination recommendations. Atlanta: CDC; 2024.
4- Schillie S, Murphy TV, Sawyer M, et al. CDC guidance for evaluating hepatitis B vaccine safety and effectiveness. MMWR Recomm Rep. 2018;67(1):1-31.
Read more...